Epeleuton is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a next-generation synthetic n-3 fatty acid small molecule drug.

Epeleuton is a new chemical entity with additional therapeutic effects compared with other n-3 fatty acids.

Epeleuton is a potential novel therapeutic option for clinical management of patients with Sickle Cell Disease that targets multiple aspects of the disease.


Epeleuton has a unique combination of effects that target two important aspects of Sickle Cell Disease:

  1. Red blood cells and Anemia
  2. Inflammation of blood vessels.

This is a unique finding because current treatments target red blood cells or inflammation, but not both.


Sickle Cell Disease

Sickle Cell Disease (SCD) is a rare inherited disorder that affects red blood cells.

People with SCD produce unusually shaped red blood cells that don’t live as long as healthy blood cells and can block blood vessels.

It is a serious and lifelong condition, and people with SCD experience many health problems.

Pain is the leading cause of hospitalization. The hallmark of SCD are these acute pain crises called vaso-occlusion that are a result of not enough oxygen reaching tissues and organs.


Sickle Cell Disease unmet need

The incidence of SCD is estimated at 300,000 to 400,000 births globally per year with an estimated prevalence of 52,000 in the EU and 100,000 in US.

SCD carries a life expectancy of 25 to 30 years below the general population.

Despite the seriousness and outcomes of SCD, few treatments are available and there is a need for additional therapies that will improve SCD clinical outcomes.


Expanded Access Statement

Afimmune Limited’s current policy on expanded access is not to offer expanded access until such time that the company has thoroughly accessed the various regulatory components and implications of such an offering. For more information, please contact [email protected]